- Home
- BH vs LTGO Comparison
BH vs LTGO Comparison
Compare BH & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BH | LTGO |
|---|---|---|
| Founded | 1934 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BH | LTGO |
|---|---|---|
| Price | $382.47 | $19.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 191.2K | ★ 581.8K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $433,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $234.92 | $17.22 |
| 52 Week High | $483.60 | $20.50 |
Technical Indicators
Market Signals| Indicator | BH | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 64.63 |
| Support Level | $361.96 | N/A |
| Resistance Level | $414.26 | N/A |
| Average True Range (ATR) | 19.86 | 1.48 |
| MACD | -1.87 | 0.14 |
| Stochastic Oscillator | 47.93 | 56.10 |
Price Performance
Historical ComparisonAbout BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.